Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
Abstract Background While tumor suppressor p53 functions primarily as a transcription factor in the nucleus, cellular stress can cause p53 to translocate to the mitochondria and directly trigger a rapid apoptotic response. We have previously shown that fusing p53 (or its DNA binding domain, DBD, alo...
| Published in: | Journal of Ovarian Research |
|---|---|
| Main Authors: | Phong Lu, Erica R. Vander Mause, Katherine E. Redd Bowman, Sarah M. Brown, Lisa Ahne, Carol S. Lim |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13048-019-0516-2 |
Similar Items
C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo
by: Robert L. Fine, et al.
Published: (2023-01-01)
by: Robert L. Fine, et al.
Published: (2023-01-01)
Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers
by: Bao Kong, et al.
Published: (2022-06-01)
by: Bao Kong, et al.
Published: (2022-06-01)
Mechanistic insights into p53‐regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells
by: Christian Marx, et al.
Published: (2021-12-01)
by: Christian Marx, et al.
Published: (2021-12-01)
Investigation into the Effect of Aspartame on the Expression of p53 and BAX in Mouse Stomach Tissue
by: Angelique Cheryl, et al.
Published: (2024-12-01)
by: Angelique Cheryl, et al.
Published: (2024-12-01)
p53’s Extended Reach: The Mutant p53 Secretome
by: Evangelos Pavlakis, et al.
Published: (2020-02-01)
by: Evangelos Pavlakis, et al.
Published: (2020-02-01)
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
by: Bryce Wallis, et al.
Published: (2023-01-01)
by: Bryce Wallis, et al.
Published: (2023-01-01)
Phenology of common beech (Fagus sylvatica L.) along the altitudinal gradient in Slovakia (Inner Western Carpathians)
by: B. Schieber, et al.
Published: (2013-04-01)
by: B. Schieber, et al.
Published: (2013-04-01)
Pyrimidine Triones as Potential Activators of p53 Mutants
by: Maryam M. Jebril Fallatah, et al.
Published: (2024-08-01)
by: Maryam M. Jebril Fallatah, et al.
Published: (2024-08-01)
HSPB1 alleviates acute-on-chronic liver failure via the P53/Bax pathway
by: Zhang Zhixiang, et al.
Published: (2024-07-01)
by: Zhang Zhixiang, et al.
Published: (2024-07-01)
Bcl-xL Reduces Chinese Giant Salamander Iridovirus-Induced Mitochondrial Apoptosis by Interacting with Bak and Inhibiting the p53 Pathway
by: Yiqun Li, et al.
Published: (2021-11-01)
by: Yiqun Li, et al.
Published: (2021-11-01)
Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers
by: Na Zhang, et al.
Published: (2025-05-01)
by: Na Zhang, et al.
Published: (2025-05-01)
Mutant P53 expression in chronic myeloid leukemia
by: Areej E. Kadhom, et al.
Published: (2013-07-01)
by: Areej E. Kadhom, et al.
Published: (2013-07-01)
Inhibition of <i>TP53</i> Mutant Oral Cancer by Reactivating p53
by: Yei-Jin Kang, et al.
Published: (2022-06-01)
by: Yei-Jin Kang, et al.
Published: (2022-06-01)
Dual roles of SIRT1 in the BAX switch through the P53 module: A mathematical modeling study
by: Nan Liu, et al.
Published: (2021-01-01)
by: Nan Liu, et al.
Published: (2021-01-01)
P53 and anti‐p53 autoantibody complex versus anti‐p53 antibody as a biomarker for gastrointestinal cancer
by: V. Hamidi Sofiani, et al.
Published: (2025-09-01)
by: V. Hamidi Sofiani, et al.
Published: (2025-09-01)
Targeting mutant p53 in cancer: the latest insights
by: Silvia Di Agostino, et al.
Published: (2019-07-01)
by: Silvia Di Agostino, et al.
Published: (2019-07-01)
Implications of Bax, Fas, and p53 in the pathogenesis of early-stage mycosis fungoides and alterations in expression following photochemotherapy
by: Fatma Aydin, et al.
Published: (2011-01-01)
by: Fatma Aydin, et al.
Published: (2011-01-01)
The E3 Ligase PIAS1 Regulates p53 Sumoylation to Control Stress-Induced Apoptosis of Lens Epithelial Cells Through the Proapoptotic Regulator Bax
by: Qian Nie, et al.
Published: (2021-06-01)
by: Qian Nie, et al.
Published: (2021-06-01)
Exploring the Functions of Mutant p53 through <i>TP53</i> Knockout in HaCaT Keratinocytes
by: Daniil Romashin, et al.
Published: (2024-02-01)
by: Daniil Romashin, et al.
Published: (2024-02-01)
Mutant p53 and ETS2, a tale of reciprocity
by: Luis Alfonso Martinez
Published: (2016-02-01)
by: Luis Alfonso Martinez
Published: (2016-02-01)
Targeting mutant p53 stabilization for cancer therapy
by: Jiajian Wang, et al.
Published: (2023-07-01)
by: Jiajian Wang, et al.
Published: (2023-07-01)
Mitigation of apoptosis-mediated neurotoxicity induced by silver nanoparticles via rutaceae nutraceuticals: P53 activation and Bax/Bcl-2 regulation
by: Rehab M. Abdel-Megeed, et al.
Published: (2022-01-01)
by: Rehab M. Abdel-Megeed, et al.
Published: (2022-01-01)
MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
by: Lin W, et al.
Published: (2024-01-01)
by: Lin W, et al.
Published: (2024-01-01)
Lipidome atlas of p53 mutant variants in pancreatic cancer
by: Kian Cotton, et al.
Published: (2025-04-01)
by: Kian Cotton, et al.
Published: (2025-04-01)
USP7 regulates growth and maintains the stemness of p53-mutant colorectal cancer cells via stabilizing of mutant p53
by: Xue Li, et al.
Published: (2024-09-01)
by: Xue Li, et al.
Published: (2024-09-01)
Mutant p53: multiple mechanisms define biologic activity in cancer
by: Michael Paul Kim, et al.
Published: (2015-11-01)
by: Michael Paul Kim, et al.
Published: (2015-11-01)
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
by: Shengliang Zhang, et al.
Published: (2022-04-01)
by: Shengliang Zhang, et al.
Published: (2022-04-01)
In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer
by: Lucie Vanikova, et al.
Published: (2025-08-01)
by: Lucie Vanikova, et al.
Published: (2025-08-01)
Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as diagnostic tools
by: Diana Spiegelberg, et al.
Published: (2025-01-01)
by: Diana Spiegelberg, et al.
Published: (2025-01-01)
Editorial: Advances in wild type and mutant p53 research in cancer
by: Olga N. Hernández-de la Cruz, et al.
Published: (2022-11-01)
by: Olga N. Hernández-de la Cruz, et al.
Published: (2022-11-01)
The efficacy of hyperthermia-based multimodal therapy is dependent on gatekeeper protein, BID
by: Sarah Helmueller, et al.
Published: (2025-12-01)
by: Sarah Helmueller, et al.
Published: (2025-12-01)
Mutant p53 in Cancer Progression and Targeted Therapies
by: Gaoyang Zhu, et al.
Published: (2020-11-01)
by: Gaoyang Zhu, et al.
Published: (2020-11-01)
Opto-p53: A light-controllable activation of p53 signaling pathway
by: Tatsuki Tsuruoka, et al.
Published: (2025-06-01)
by: Tatsuki Tsuruoka, et al.
Published: (2025-06-01)
New records of Parmelia ernstiae and P. serrana (Ascomycota, Parmeliaceae) in Poland
by: Emilia Ossowska, et al.
Published: (2016-01-01)
by: Emilia Ossowska, et al.
Published: (2016-01-01)
Searching for a cut-off point for p53 immunohistochemistry as evidence of TP53 mutations
by: Ilay Caliskan, et al.
Published: (2024-03-01)
by: Ilay Caliskan, et al.
Published: (2024-03-01)
p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners
by: Anamari Brdar, et al.
Published: (2025-09-01)
by: Anamari Brdar, et al.
Published: (2025-09-01)
Vodní měkkýši CHKO Brdy
by: Luboš Beran, et al.
Published: (2022-12-01)
by: Luboš Beran, et al.
Published: (2022-12-01)
Molluscs of the Krkonoše Mts. (Czech Republic)
by: Lucie Juřičková, et al.
Published: (2008-09-01)
by: Lucie Juřičková, et al.
Published: (2008-09-01)
Implementasi Kurikulum di Madrasah Tsanawiyah Salafiyah Pondok Pesantren Tremas Pacitan
by: M. Suyudi, et al.
Published: (2021-01-01)
by: M. Suyudi, et al.
Published: (2021-01-01)
P53, Bcl2 and Bax Expression and Apoptosis in Perifosine and Vitamin D-Treated Endometrial Cancer Cell Line (HEC1A)
by: Meryem İlkay Karagül, et al.
Published: (2018-12-01)
by: Meryem İlkay Karagül, et al.
Published: (2018-12-01)
Similar Items
-
C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo
by: Robert L. Fine, et al.
Published: (2023-01-01) -
Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers
by: Bao Kong, et al.
Published: (2022-06-01) -
Mechanistic insights into p53‐regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells
by: Christian Marx, et al.
Published: (2021-12-01) -
Investigation into the Effect of Aspartame on the Expression of p53 and BAX in Mouse Stomach Tissue
by: Angelique Cheryl, et al.
Published: (2024-12-01) -
p53’s Extended Reach: The Mutant p53 Secretome
by: Evangelos Pavlakis, et al.
Published: (2020-02-01)
